NEW YORK, Feb. 27, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP
(www.kaplanfox.com) is investigating Akorn, Inc. ("Akorn" or the
"Company") (NASDAQ: AKRX), a specialty generic pharmaceutical
company, concerning potential securities law violations.
Investors who purchased Akorn securities may be affected.
On April 7, 2017, Akorn confirmed
that the Company was in discussions with Fresenius Kabi, a
subsidiary of Fresenius SE & Co. KGaA ("Fresenius"), regarding
a potential acquisition of Akorn. Following this news,
Akorn's shares increased in price by over 18%, $4.55 per share, to close at $29.77 per share on April
7, 2017.
On February 26, 2018, after the
market closed, Fresenius, which had been expected to close the
acquisition of Akorn in the coming weeks, announced that it is
"conducting an independent investigation, using external experts,
into alleged breaches of FDA data integrity requirements relating
to product development at Akorn, Inc."
On February 27, 2018, following
the above disclosures, Akorn's shares plummeted in midday trading
by over $10 per share, or about 34%,
on heavy trading volume.
If you are an investor in Akorn and would like to discuss our
investigation, please contact us by emailing pmayer@kaplanfox.com
or by calling 800-290-1952.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP,
with offices in New York,
San Francisco, Los Angeles, Chicago and New
Jersey, has many years of experience in prosecuting investor
class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit
our website at www.kaplanfox.com. If you have any questions
about this Notice, the action, your rights, or your interests,
please contact:
Frederic S. Fox
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: ffox@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California
94104
(415) 772-4700
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
View original
content:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-announces-investigation-of-akorn-inc-300605178.html
SOURCE Kaplan Fox &
Kilsheimer LLP